BACKGROUND: Microalbuminuria (MAU) is a marker for endothelial dysfunction and a predictor of cardiovascular events. Cardiovascular risk and mortality are mainly influenced by associated morbidities and risk factors. METHODS AND RESULTS: The present analysis aimed to investigate the relationship between the number of cardiovascular comorbidities and both the prevalence of MAU and the extent of albuminuria (measured as urinary albumin excretion, UAE) in 21,867 high-risk hypertensive patients included in the I-SEARCH study. A total of 6,945 patients (32 %) suffered from at least one comorbidity, out of which 5,437 patients (25 %) had one cardiovascular comorbidity, 1,163 (5 %) patients had two, and 345 (2 %) had ≥3. The prevalence of MAU increased from 54 % in patients without cardiovascular comorbidity to 74 % in the presence of ≥3 comorbidities (p < 0.01). In a multivariate analysis, the presence of ≥3 cardiovascular comorbidities nearly doubled the risk for MAU (HR 1.79, CI 1.07-2.68, p = 0.025). Compared to other comorbidities, patients with left ventricular hypertrophy had the highest prevalence of MAU (68 %, p < 0.01). The extent of UAE was related to the number of concomitant disease and increased significantly in patients with ≥3 comorbidities compared to patients with no comorbidity (UAE of 80 mg/L: 12-22 %, p < 0.01; UAE of 150 mg/L: 8-19 %, p < 0.01). CONCLUSIONS: In hypertensive patients at high cardiovascular risk, both the prevalence of MAU and the extent of albuminuria increase with the number of comorbidities.
BACKGROUND: Microalbuminuria (MAU) is a marker for endothelial dysfunction and a predictor of cardiovascular events. Cardiovascular risk and mortality are mainly influenced by associated morbidities and risk factors. METHODS AND RESULTS: The present analysis aimed to investigate the relationship between the number of cardiovascular comorbidities and both the prevalence of MAU and the extent of albuminuria (measured as urinary albumin excretion, UAE) in 21,867 high-risk hypertensivepatients included in the I-SEARCH study. A total of 6,945 patients (32 %) suffered from at least one comorbidity, out of which 5,437 patients (25 %) had one cardiovascular comorbidity, 1,163 (5 %) patients had two, and 345 (2 %) had ≥3. The prevalence of MAU increased from 54 % in patients without cardiovascular comorbidity to 74 % in the presence of ≥3 comorbidities (p < 0.01). In a multivariate analysis, the presence of ≥3 cardiovascular comorbidities nearly doubled the risk for MAU (HR 1.79, CI 1.07-2.68, p = 0.025). Compared to other comorbidities, patients with left ventricular hypertrophy had the highest prevalence of MAU (68 %, p < 0.01). The extent of UAE was related to the number of concomitant disease and increased significantly in patients with ≥3 comorbidities compared to patients with no comorbidity (UAE of 80 mg/L: 12-22 %, p < 0.01; UAE of 150 mg/L: 8-19 %, p < 0.01). CONCLUSIONS: In hypertensivepatients at high cardiovascular risk, both the prevalence of MAU and the extent of albuminuria increase with the number of comorbidities.
Authors: Hans Ibsen; Michael H Olsen; Kristian Wachtell; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Ying Wan Journal: Hypertension Date: 2005-01-17 Impact factor: 10.190
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: Thomas J Wang; Jane C Evans; James B Meigs; Nader Rifai; Caroline S Fox; Ralph B D'Agostino; Daniel Levy; Ramachandran S Vasan Journal: Circulation Date: 2005-02-28 Impact factor: 29.690
Authors: Janine Pöss; Christian Ukena; Felix Mahfoud; Christoph Gensch; Christian Werner; Martin Thoenes; Peter Bramlage; Massimo Volpe; Ulrich Laufs; Michael Böhm Journal: Eur J Prev Cardiol Date: 2011-09-07 Impact factor: 7.804
Authors: Hermann Haller; Sadayoshi Ito; Joseph L Izzo; Andrzej Januszewicz; Shigehiro Katayama; Jan Menne; Albert Mimran; Ton J Rabelink; Eberhard Ritz; Luis M Ruilope; Lars C Rump; Giancarlo Viberti Journal: N Engl J Med Date: 2011-03-10 Impact factor: 91.245
Authors: Folkert W Asselbergs; Gilles F H Diercks; Hans L Hillege; Ad J van Boven; Wilbert M T Janssen; Adriaan A Voors; Dick de Zeeuw; Paul E de Jong; Dirk J van Veldhuisen; Wiek H van Gilst Journal: Circulation Date: 2004-10-18 Impact factor: 29.690
Authors: Michael Böhm; Martin Thoenes; Nicolas Danchin; Peter Bramlage; Pablo La Puerta; Massimo Volpe Journal: J Hypertens Date: 2007-11 Impact factor: 4.844
Authors: R Pedrinelli; O Giampietro; F Carmassi; E Melillo; G Dell'Omo; G Catapano; E Matteucci; L Talarico; M Morale; F De Negri Journal: Lancet Date: 1994-07-02 Impact factor: 79.321
Authors: Oliver Dörr; Sebastian Ewen; Christoph Liebetrau; Helge Möllmann; Luise Gaede; Dominik Linz; Mathias Hohl; Christian Troidl; Timm Bauer; Michael Böhm; Christian Hamm; Felix Mahfoud; Holger Nef Journal: Clin Res Cardiol Date: 2015-05-26 Impact factor: 5.460